Meta-analysis of the prognostic value of long non-coding RNA AFAP1-AS1 for cancer patients in China
Metrics: PDF 690 views | HTML 1726 views | ?
Rui-Hua Liu1,*, Ming-Ying Wang1,3,*, Ling-Yun Chen2,3,*, Zhi-Jie Yin1, Qian-Kun Ji1, Yang-Yang Wang1 and Bao-Zhe Jin1
1Department of Neurosurgery, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan Province, People’s Republic of China
2Department of Operating Theatre, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan Province, People’s Republic of China
3Department of Nursing, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453000, Henan Province, People’s Republic of China
*These authors contributed equally to this work
Bao-Zhe Jin, email: firstname.lastname@example.org
Keywords: LncRNA; AFAP1-AS1; neoplasms; prognosis; metastasis
Received: August 29, 2017 Accepted: October 28, 2017 Published: December 21, 2017
LncRNA actin filament-associated protein 1 antisense RNA 1 (AFAP1-AS1) is often dysregulated in cancer. We performed this meta-analysis to clarify the usefulness of AFAP1-AS1 as a prognostic marker in malignant tumors. The PubMed, Medline, OVID, Cochrane Library, and Web of Science databases were searched from inception to Augest 7, 2017. Sixteen studies with a total of 1,386 patients were included in the study. The pooled hazard ratio (HR) suggested high AFAP1-AS1 expression correlated with poor overall survival (OS) (HR = 1.98, 95% confidence interval (CI): 1.71–2.28), disease-free survival (DFS) (HR = 1.54, 95% CI: 1.22–1.95), and progression-free survival (PFS) (HR = 2.17, 95% CI:1.64–2.88) in cancer patients, without obvious heterogeneity. High AFAP1-AS1 expression also correlated with larger tumor size (odds ratio (OR) = 2.04, 95% CI: 1.54–2.72), advanced tumor stage (OR=2.35, 95% CI: 1.70–3.26), poor histological grade (OR =1.39, 95% CI: 1.02–1.90), lymph node metastasis (OR = 2.71, 95% CI: 1.98–3.72) and distant metastasis (OR = 2.96, 95% CI: 2.03–4.32). Thus high AFAP1-AS1 expression is predictive of poor OS, DFS, PFS, lymph node metastasis, distant metastasis, histological grade, larger tumor size and tumor stage, which suggests high AFAP1-AS1 expression may serve as a novel biomarker of poor prognosis in cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.